Using Kaplan-Meier log-rank analyses, patients with mutant p53 breast cancer had significantly worse disease-free survival and overall survival than those with wild-type p53 breast cancer (Kaplan-Meier log-rank test, χ2 = 10.51, 1 df, P = 0.001; and χ2 = 6.55, 1 df, P = 0.010, respectively) (Figure S1 in Additional file 3), with a more than three times increased risk of recurrence and death (hazard ratio (HR) = 3.48 and HR = 3.16, respectively). This evidence concerns the gene TP53 and breast cancer.